Board of Directors

Hank Plain has served as Chairman of the Board of Directors of Satiety since 2001. In August 2007, Hank joined Morgenthaler Ventures as a partner on their Life Sciences Team, which invests in early stage Medical Device and Biotech companies. Since July 2000, he has been Vice-Chairman of the Foundry, where he serves as an active Director and Advisor to medical device companies of all stages, providing expertise in founding, funding, product development and operational management. Previously, Hank was President and CEO of Perclose. From 1993 until May 2000, he led Perclose from the product concept stage through product development, regulatory approvals and successful market launch to become the worldwide leader in vascular access site closure devices with over $100 million in sales in 2000. He successfully directed Perclose through an IPO, a secondary offering and acquisition by Abbott Laboratories for $650 million in November 1999. Prior to joining Perclose, Hank was with Eli Lilly and Company for 12 years, where he held various marketing and general management positions in the Pharmaceutical and Medical Device business units. He is Chairman of the Board of Directors for Emphasys Medical and Xtent, and is a Director of Acclarent, Access Closure, Ardian, Cabochon Aesthetics, Cierra, Miramar, The Foundry, and the Pacific Foundation for Cardiovascular Research. Hank was also Chairman of the Board of Embolic Protection (acquired by Boston Scientific), and was a Director of TransVascular, Inc. (acquired by Medtronic). He is on the Board of Trustees of Woodside Priory School in Portola Valley, CA.

Mike Bates currently serves as Director and Audit Committee Chairman of Satiety, Inc, Emphasys Medical and BARRX Medical. He has more than 25 years of experience in corporate financial management, including 16 years in the life science and medical technology industries. Mr. Bates was Chief Financial Officer of St. Francis Medical Technologies, developer of a minimally invasive device and procedure to treat lumbar spinal stenosis, from 2005 until its sale to Kyphon Inc. in January 2007 for $725 million. Mr. Bates previously served as Vice President of Finance and Administration, CFO, for Silicon Genetics, a bioinformatics company from April of 2000 through to its sale to Agilent Technologies in October 2004. During 1999 Mr. Bates served as Vice President of Finance and CFO for Collagen Aesthetics Inc., a publicly-traded medical device company that was sold to Inamed Corporation in 1999. Prior to Collagen, Mr. Bates was Vice President of Finance and Administration and CFO at Penederm Incorporated, a publicly-traded specialty pharmaceutical company focused on dermatology and topical drug delivery technologies, which was sold to Mylan Laboratories in 1998.  Mr. Bates currently serves as a Board member of the Northern California Chapter of the Association of Bioscience Finance Officers (ABFO) and was its President in 2005 and 2006. Mr. Bates is a certified public accountant (inactive), having begun his career at Deloitte and Touche LLP and has also held positions at Tandem Computers Inc. He is a graduate of California State University at Hayward and received an MBA in Finance from the University of California at Berkeley.

Tom is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and vintner. He has been involved with a wide spectrum of innovations, serving as founder/co-founder, and Chairman/Board Member of over 33 various business and research companies, based on devices designed and developed by Fogarty Engineering, Inc. During the past 40 years, he has acquired over 100 surgical patents, including the “industry standard” Fogarty balloon embolectomy catheter and the widely used Aneurx Stent Graft that replaces open-heart abdominal aortic aneurysm (AAA) surgery and was inducted into the Inventors Hall of Fame in December 2001. Tom received his undergraduate degree from Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon and later served as Medical Staff President at Stanford Medical Center from 1973-1975. After thirteen years directing the Cardiovascular Surgery Program at Sequoia Hospital, he returned to academic life at Stanford University School of Medicine in July 1993, as Professor of Surgery. Dr. Fogarty resigned from Stanford in 2001 and now spends a majority of his time creating new medical devices with Fogarty Engineering. Tom is Founder and Chairman of the Board of Directors of Arbor Surgical, Bacchus Vascular, Novare, is Founder and Board member of Fogarty Engineering, Satiety and Thomas Fogarty Winery & Vineyards and serves on the Board of Directors of Acorn Cardiovascular, Avantis Medical Systems, Biolucent, Evalve, Gauda, Restoration Robotics, Sleep Solutions, Starion Instruments and Tibion.

John has been involved in founding, financing, managing and advising healthcare companies since 1982. He began his career at Morgan Stanley in New York, where he co-founded the Healthcare Group in the Corporate Finance Department and was later the original healthcare partner at Morgan Stanley Ventures. He then was an operating executive for six years as Executive Vice President of Acuson Corporation (an NYSE-traded company that is now part of Siemens), where he ran Marketing and led the cross-functional management of the company's product introductions. In 1995, he licensed the technology that served as the core of Intuitive Surgical, Inc. (NASDAQ:ISRG), co-founded Intuitive and raised its initial venture capital. He then spent two years as the West Coast partner at the Private Equity group of Chancellor Capital Management (now INVESCO), before founding Skyline in 1997. He has experience with most of the major sectors of the healthcare investment market including medical devices, information technology, small molecule and protein therapeutics, biochips and diagnostics. He received a B.A. from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance. He was the co-author of The Official MBA Handbook, which spent 16 weeks on the New York Times bestseller list in 1982.

Bryan joined Venrock as a Kauffman Fellow in 1997. Previously, he earned his Ph.D. in Chemistry & Chemical Biology at Harvard University and, prior to his doctoral program, held corporate finance positions at Kidder, Peabody and Co.  Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, he was named to healthspottr’s 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes’ Midas List in 2008 and 2009.  Bryan’s previous investments include athenahealth, Illumina, Sirna Therapeutics, and XenoPort.  He serves on the boards of Achaogen, Cerulean Pharma, CodeRyte, Fate Therapeutics, Ikaria, Intarcia, Ironwood Pharmaceuticals, Surface Logix, Ventana, Vitae Pharmaceuticals, and Zeltiq Aesthetics.  Bryan earned his B.A. in Chemistry from Dartmouth College.

Rod joined Three Arch Partners as a Venture Partner in May 2006. Prior to Three Arch Partners, Rod was President and CEO of Vivant Medical, a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Targesome, Chairman & CEO of General Surgical Innovations, also a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Focus Surgery, President of Toshiba America MRI, and President & COO of Diasonics.

Rod holds a BS degree in Industrial Engineering from Stanford University and an MBA from the Harvard Business School.